


## Avendus advises Nichepharm Lifesciences and the Sobti Family, on Its complete acquisition of 24% shares from Swedish - Based Recipharm AB

August 2024 • Mumbai

	DEAL VALUE	Undisclosed
	SERVICE	Mergers & Acquisitions
	SECTOR	Healthcare

Nichepharm Lifesciences Private Limited, led by the Sobti family, announced the acquisition of the remaining 24% shares from their joint venture partner, Recipharm AB (Sweden), thereby restoring 100% ownership of the company. Nichepharm, under the stewardship of Dr. Chetan Sobti and Nitin Sobti, had entered into a joint venture with Recipharm in 2019. The partnership has fostered substantial growth and fruitful collaboration over the past five years.

**| Avendus advised Nichepharm Lifesciences on the transaction and also supported the Sobti Family with strategic wealth advisory.**

Commenting on the announcement, **Dr. Chetan Sobti and Nitin Sobti, Co-Founders and Directors, Nichepharm Lifesciences** said, “This strategic maneuver marks a pivotal moment in Nichepharm’s trajectory. We remain committed to delivering cutting-edge pharmaceutical solutions, while upholding stringent standards of quality to ensure ongoing customer satisfaction. We are now poised to accelerate the company’s development initiatives, broaden its product portfolio, and explore new opportunities in global markets.”

**Anshul Gupta, Managing Director and Head, Healthcare Investment Banking, Avendus Capital** said, “Avendus is pleased that Sobti family has achieved a timely resolution of the shareholding structure of Nichepharm, which will allow them greater flexibility in accelerating the Company’s growth. We remain excited about its future prospects, given a large global market opportunity. We wish the family success in their continued quest to create sustainable value for all their stakeholders.”

**Shravan Sreenivasula, Executive Director, Investment Solutions Group, Avendus Wealth Management** added, “Avendus Wealth has had the privilege of partnering with the Sobti family over the past decade, supporting their wealth management needs. It has been a pleasure to guide them in securing the necessary funds to

acquire the stake from their JV partner. We wish Nichepharm continued success as it embarks on the next phase of growth.”

## | About Avendus

**Avendus Group** is a leading financial services firm with a presence in the areas of Investment Banking, Institutional Equities, Wealth Management, Credit Solutions and Asset Management. Established in 1999 in Mumbai, India, Avendus is today present in 10 cities across India, US and Singapore. Avendus partners with the Indian entrepreneur ecosystem to provide differentiated solutions that enable clients to meet their strategic aspirations.

**Avendus Capital**, the investment banking arm, is consistently ranked among the top investment banks in the country on the back of its in-depth domain understanding and a best in the class track record of domestic and cross-border transactions. Avendus’ wide range of clients is testimony to its ability to serve its corporates throughout their life cycle – from growth stage funding to large-sized transactions, M&A advisory and access to public markets.

**Avendus Capital Inc.**, New York and **Avendus Pte Ltd.**, Singapore are both Avendus Group entities offering services to clients in the US and Southeast Asia respectively.

For more information, please visit [www.avendus.com](http://www.avendus.com)

### **Deal Release**

Contact: Lynette D’souza  
Tel: +91 9920847823  
Email: [lynette.dsouza@avendus.com](mailto:lynette.dsouza@avendus.com)

### **Avendus Capital Private Limited**

Regd. Office: 901, Platina, 9th Floor, Plot No. C-59,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400051